Elizabeth E. Sugg

Allele-specific activation of genetically engineered receptors.

Catherine D. Strader, T. J. Gaffney, Elizabeth E. Sugg et al. · Journal of Biological Chemistry · 1991 · 233 citations · Full text

Medicine, Molecular Biology, Pharmacology +17

Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”

Christopher Aquino, Duncan Armour, Judd Berman et al. · Journal of Medicinal Chemistry · 1996 · 101 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Determination of the three-dimensional structure of iberiotoxin in solution by proton nuclear magnetic resonance spectroscopy

Bruce A. Johnson, Elizabeth E. Sugg · Biochemistry · 1992 · 92 citations

Life Sciences, Biochemistry, Toxicology +9

Optimization of 3-(1<i>H</i>-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists

Brad R. Henke, Christopher Aquino, Larry S. Birkemo et al. · Journal of Medicinal Chemistry · 1997 · 86 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Synthetic charybdotoxin-iberiotoxin chimeric peptides define toxin binding sites on calcium-activated and voltage-dependent potassium channels

Kathleen M. Giangiacomo, Elizabeth E. Sugg, Margarita García‐Calvo et al. · Biochemistry · 1993 · 79 citations

Natural Sciences, Neuroscience, Pharmacology +17